00928.HK
King International Investment Limited
HKSE · Healthcare · Medical - Diagnostics & Research · HK
HKD 0.65
−10.96%Year over year
Reported trailing growth
- Revenue
- +251.4%
- EBITDA
- +150.1%
- EBIT
- +145.0%
- EPS
- +103.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.8%
- EBITDA
- -41.0%
- EBIT
- -28.3%
- Net income
- -65.9%
- EPS
- -67.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026